MXPA02012708A - Moduladores ppar-gamma de quinolinilo y benzotiazolilo. - Google Patents
Moduladores ppar-gamma de quinolinilo y benzotiazolilo.Info
- Publication number
- MXPA02012708A MXPA02012708A MXPA02012708A MXPA02012708A MXPA02012708A MX PA02012708 A MXPA02012708 A MX PA02012708A MX PA02012708 A MXPA02012708 A MX PA02012708A MX PA02012708 A MXPA02012708 A MX PA02012708A MX PA02012708 A MXPA02012708 A MX PA02012708A
- Authority
- MX
- Mexico
- Prior art keywords
- benzothiazolyl
- quinolinyl
- ppar
- substituted
- unsubstituted
- Prior art date
Links
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 title 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 2
- 108010016731 PPAR gamma Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- -1 2-benzothiazolyl Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Quinoline Compounds (AREA)
- Holo Graphy (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21481000P | 2000-06-28 | 2000-06-28 | |
| PCT/US2001/020756 WO2002000633A1 (en) | 2000-06-28 | 2001-06-27 | Quinolinyl and benzothiazolyl ppar-gamma modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02012708A true MXPA02012708A (es) | 2003-09-22 |
Family
ID=22800496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02012708A MXPA02012708A (es) | 2000-06-28 | 2001-06-27 | Moduladores ppar-gamma de quinolinilo y benzotiazolilo. |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1296967B1 (enExample) |
| JP (1) | JP4515026B2 (enExample) |
| KR (1) | KR100771286B1 (enExample) |
| CN (1) | CN1243741C (enExample) |
| AT (1) | ATE327984T1 (enExample) |
| AU (2) | AU2001271637B2 (enExample) |
| BR (1) | BRPI0112115B8 (enExample) |
| CA (1) | CA2412723C (enExample) |
| CY (1) | CY1105126T1 (enExample) |
| CZ (1) | CZ302982B6 (enExample) |
| DE (1) | DE60120163T2 (enExample) |
| DK (1) | DK1296967T3 (enExample) |
| EA (1) | EA005976B1 (enExample) |
| ES (1) | ES2265435T3 (enExample) |
| HK (1) | HK1052351B (enExample) |
| HU (1) | HUP0301482A3 (enExample) |
| IL (2) | IL153461A0 (enExample) |
| MX (1) | MXPA02012708A (enExample) |
| NO (1) | NO325448B1 (enExample) |
| NZ (1) | NZ523229A (enExample) |
| PL (1) | PL214670B1 (enExample) |
| PT (1) | PT1296967E (enExample) |
| SK (1) | SK288236B6 (enExample) |
| WO (1) | WO2002000633A1 (enExample) |
| ZA (1) | ZA200210283B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| IL160845A0 (en) | 2001-09-14 | 2004-08-31 | Tularik Inc | Linked biaryl compounds |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| AU2003248549B2 (en) | 2002-05-24 | 2010-04-08 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| AU2003298661B2 (en) | 2002-11-18 | 2007-05-10 | Chemocentryx, Inc. | Aryl sulfonamides |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| ES2530235T3 (es) | 2003-02-13 | 2015-02-27 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos |
| EP1613298A4 (en) * | 2003-04-11 | 2007-10-03 | Univ Tennessee Res Foundation | Lysophosphatidic Acid Analysis and Inhibition of Neointimal Formation |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| DE602005020313D1 (de) | 2004-08-12 | 2010-05-12 | Amgen Inc | Bisaryl-sulfonamide |
| KR20110084339A (ko) | 2005-07-09 | 2011-07-21 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체 |
| US7820721B2 (en) | 2006-01-25 | 2010-10-26 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| EP1976510A4 (en) | 2006-01-25 | 2010-06-09 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER |
| JP2009525982A (ja) | 2006-02-02 | 2009-07-16 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の治療のための化合物 |
| JP5291471B2 (ja) * | 2006-02-15 | 2013-09-18 | アボット・ラボラトリーズ | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
| US8030324B2 (en) * | 2006-09-21 | 2011-10-04 | Piramal Life Sciences Ltd. | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia |
| WO2012162463A1 (en) * | 2011-05-25 | 2012-11-29 | Janssen Pharmaceutica Nv | Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation |
| CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| CN109651208B (zh) * | 2017-10-10 | 2022-01-04 | 中国科学院上海药物研究所 | N-芳基磺酰胺类化合物，其药物组合物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3632329A1 (de) * | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| AU759255B2 (en) * | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
| WO2001000579A1 (en) * | 1999-06-30 | 2001-01-04 | Tularik Inc. | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY |
-
2001
- 2001-06-27 HK HK03104574.3A patent/HK1052351B/en not_active IP Right Cessation
- 2001-06-27 PT PT01950669T patent/PT1296967E/pt unknown
- 2001-06-27 KR KR1020027017927A patent/KR100771286B1/ko not_active Expired - Lifetime
- 2001-06-27 EP EP01950669A patent/EP1296967B1/en not_active Expired - Lifetime
- 2001-06-27 IL IL15346101A patent/IL153461A0/xx active IP Right Grant
- 2001-06-27 MX MXPA02012708A patent/MXPA02012708A/es active IP Right Grant
- 2001-06-27 HU HU0301482A patent/HUP0301482A3/hu unknown
- 2001-06-27 PL PL359996A patent/PL214670B1/pl unknown
- 2001-06-27 AT AT01950669T patent/ATE327984T1/de active
- 2001-06-27 DK DK01950669T patent/DK1296967T3/da active
- 2001-06-27 CA CA2412723A patent/CA2412723C/en not_active Expired - Lifetime
- 2001-06-27 EA EA200300078A patent/EA005976B1/ru not_active IP Right Cessation
- 2001-06-27 CZ CZ20024197A patent/CZ302982B6/cs not_active IP Right Cessation
- 2001-06-27 NZ NZ523229A patent/NZ523229A/en not_active IP Right Cessation
- 2001-06-27 AU AU2001271637A patent/AU2001271637B2/en not_active Expired
- 2001-06-27 ES ES01950669T patent/ES2265435T3/es not_active Expired - Lifetime
- 2001-06-27 DE DE60120163T patent/DE60120163T2/de not_active Expired - Lifetime
- 2001-06-27 AU AU7163701A patent/AU7163701A/xx active Pending
- 2001-06-27 CN CNB018120172A patent/CN1243741C/zh not_active Expired - Lifetime
- 2001-06-27 JP JP2002505381A patent/JP4515026B2/ja not_active Expired - Lifetime
- 2001-06-27 SK SK1835-2002A patent/SK288236B6/sk not_active IP Right Cessation
- 2001-06-27 BR BRPI0112115A patent/BRPI0112115B8/pt not_active IP Right Cessation
- 2001-06-27 WO PCT/US2001/020756 patent/WO2002000633A1/en not_active Ceased
-
2002
- 2002-12-16 IL IL153461A patent/IL153461A/en unknown
- 2002-12-19 ZA ZA2002/10283A patent/ZA200210283B/en unknown
- 2002-12-20 NO NO20026156A patent/NO325448B1/no not_active IP Right Cessation
-
2006
- 2006-08-07 CY CY20061101099T patent/CY1105126T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU7163701A (en) | Quinolinyl and benzothiazolyl ppar-gamma modulators | |
| PL340451A1 (en) | Safe information transfer form revealing any attempts of manipulations by unauthorised persons | |
| IL103614A (en) | Carboxamides for controlling botrytis and certain novel such compounds | |
| TR199902357T2 (xx) | Yeni bile�imler. | |
| NO930839L (no) | Fremgangsmaate ved identifikasjon av hemmelige datameldinger | |
| ATE40684T1 (de) | (benzoyl-4-piperidino)-2-phenyl-1alkanolderivate, ihre herstellung und ihre verwendung als heilmittel. | |
| ZA97478B (en) | Halogenopyrimidines. | |
| AU574449B2 (en) | Nitrification-inhibiting 1-hydroxypyrazole | |
| HUT42092A (en) | Process for production of derivatives of 3-vinil and 3-ethinil-beta-carbolin and medical preparatives containing thereof | |
| NO991686L (no) | Anvendelse av sarkosinater som asfaltendispergatorer | |
| AU569326B2 (en) | 2-(n-pyrrolidino)-3-isobutoxy-n-substituted phenyl-n-benzyl-propylamines | |
| IL106469A0 (en) | Novel pyridyl-and pyrimidylpiperazine derivatives | |
| DE69706355D1 (de) | Alkylendiamin-Derivate als Arzneimittel zur Behandlung von Geschwüren und Hemmung von Helicobacter pylori | |
| FI915025A0 (fi) | 8-azabicyklo(3,2,1) oktylalkyltiazolidinoner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel. | |
| FI972850A0 (fi) | Optisesti vaalennettujen muovien käyttö paperin päällystyslietteiden vaalentamiseksi optisesti ja tällä tavoin optisesti vaalennettuja paperin päällystyslietteitä | |
| FR2701988B1 (fr) | Dispositif de sécurité de fermetures de portes. | |
| EP0353339A3 (en) | A process for the production of poly(3-mono or 3,5-disubstituted-4-acetoxystryrenes), their copolymers and hydrolysis thereof | |
| ATE203989T1 (de) | N-acylpiperazinderivat, antibakterielle und gegen geschwüre wirksame medikamente | |
| GR75012B (enExample) | ||
| FR349345A (fr) | Dispositif de sécurité contre l'effraction des portes | |
| SE9803930D0 (sv) | Sätt och anordning för att skydda DVD-Datamediaprodukter från otillåten användning och kopiering | |
| DK0527298T3 (da) | Fremgangsmåde til fremstilling af pipazetate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights | ||
| HC | Change of company name or juridical status |